» Articles » PMID: 29530893

Exercise Therapy and Cardiovascular Toxicity in Cancer

Overview
Journal Circulation
Date 2018 Mar 14
PMID 29530893
Citations 99
Authors
Affiliations
Soon will be listed here.
Abstract

Cardio-oncology is an emerging discipline focused predominantly on the detection and management of cancer treatment-induced cardiac dysfunction (cardiotoxicity), which predisposes to development of overt heart failure or coronary artery disease. The direct adverse consequences, as well as those secondary to anticancer therapeutics, extend beyond the heart, however, to affect the entire cardiovascular-skeletal muscle axis (ie, whole-organism cardiovascular toxicity). The global nature of impairment creates a strong rationale for treatment strategies that augment or preserve global cardiovascular reserve capacity. In noncancer clinical populations, exercise training is an established therapy to improve cardiovascular reserve capacity, leading to concomitant reductions in cardiovascular morbidity and its attendant symptoms. Here, we overview the tolerability and efficacy of exercise on cardiovascular toxicity in adult patients with cancer. We also propose a conceptual research framework to facilitate personalized risk assessment and the development of targeted exercise prescriptions to optimally prevent or manage cardiovascular toxicity after a cancer diagnosis.

Citing Articles

Prevention of cancer-therapy related cardiac dysfunction.

Haj-Yehia E, Michel L, Mincu R, Rassaf T, Totzeck M Curr Heart Fail Rep. 2025; 22(1):9.

PMID: 39969700 PMC: 11839799. DOI: 10.1007/s11897-025-00697-x.


Role of Cardio-Oncology Rehabilitation in Hematopoietic Stem Cell Transplantation and Chimeric Antigen Receptor T-Cell (CAR-T) Therapy.

Moriyama S, Kondo M, Awamura R, Hieda M, Fukata M Circ Rep. 2025; 7(2):59-65.

PMID: 39931708 PMC: 11807699. DOI: 10.1253/circrep.CR-24-0161.


Demographics and Health Characteristics Associated With the Likelihood of Participating in Digitally Delivered Exercise Rehabilitation for Improving Heart Health Among Breast Cancer Survivors: Cross-Sectional Survey Study.

Jones T, Edbrooke L, Rawstorn J, Denehy L, Hayes S, Maddison R JMIR Cancer. 2024; 10:e51536.

PMID: 39697144 PMC: 11683507. DOI: 10.2196/51536.


Variability in resistance training trajectories of breast cancer patients undergoing therapy.

Koeppel M, Steindorf K, Schmidt M, Rosenberger F, Wiskemann J Support Care Cancer. 2024; 33(1):12.

PMID: 39656317 PMC: 11631991. DOI: 10.1007/s00520-024-09001-4.


Trends in exercise initiation and participation among employed breast cancer survivors undergoing curative treatment.

Oza S, Patil S, Sampathkumar Y, Gany F, Blinder V Breast Cancer Res Treat. 2024; 209(3):637-645.

PMID: 39480554 DOI: 10.1007/s10549-024-07526-0.


References
1.
Rogers L, Courneya K, Anton P, Hopkins-Price P, Verhulst S, Vicari S . Effects of the BEAT Cancer physical activity behavior change intervention on physical activity, aerobic fitness, and quality of life in breast cancer survivors: a multicenter randomized controlled trial. Breast Cancer Res Treat. 2014; 149(1):109-19. PMC: 4435784. DOI: 10.1007/s10549-014-3216-z. View

2.
Yeh R, Kramer D . Decision Tools to Improve Personalized Care in Cardiovascular Disease: Moving the Art of Medicine Toward Science. Circulation. 2017; 135(12):1097-1100. PMC: 5363276. DOI: 10.1161/CIRCULATIONAHA.116.024247. View

3.
Koelwyn G, Khouri M, Mackey J, Douglas P, Jones L . Running on empty: cardiovascular reserve capacity and late effects of therapy in cancer survivorship. J Clin Oncol. 2012; 30(36):4458-61. PMC: 3518726. DOI: 10.1200/JCO.2012.44.0891. View

4.
Deo R . Machine Learning in Medicine. Circulation. 2015; 132(20):1920-30. PMC: 5831252. DOI: 10.1161/CIRCULATIONAHA.115.001593. View

5.
Sarnak M, Tighiouart H, Manjunath G, MacLeod B, Griffith J, Salem D . Anemia as a risk factor for cardiovascular disease in The Atherosclerosis Risk in Communities (ARIC) study. J Am Coll Cardiol. 2002; 40(1):27-33. DOI: 10.1016/s0735-1097(02)01938-1. View